Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

Sven R. Olson, Steven Koprowski, Justine Hum, Owen McCarty, Thomas Deloughery, Joseph J. Shatzel

Research output: Contribution to journalArticle

Abstract

Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms including reduced platelet function and number, leading to challenging peri-operative planning. Hepatic thrombopoietin (TPO) synthesis is reduced in CLD, leading to several recent randomized, placebo-controlled trials examining the utility of TPO-mimetics to increase platelet counts prior to surgery. While these trials do suggest that TPO-mimetics are efficacious at increasing platelet counts in patients with CLD and have led to several recent drug approvals in this space by the U.S. Food & Drug Administration, it remains unclear whether these results translate to the relevant clinical endpoint of reduced perioperative bleeding rate and severity. In this article, we review several recently-published, phase 3 trials on the TPO-mimetics eltrombopag, avatrombopag and lusutrombopag, and discuss the clinical significance of their results.

Original languageEnglish (US)
JournalPlatelets
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Thrombopoietin
Thrombocytopenia
Liver Diseases
Chronic Disease
Platelet Count
Hemorrhage
Drug Approval
Hemostatics
Randomized Controlled Trials
Placebos
Food
Liver
Pharmaceutical Preparations

Keywords

  • Bleeding
  • Platelets
  • thrombopoietin

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution? / Olson, Sven R.; Koprowski, Steven; Hum, Justine; McCarty, Owen; Deloughery, Thomas; Shatzel, Joseph J.

In: Platelets, 01.01.2018.

Research output: Contribution to journalArticle

@article{afa47cfb92fe432f8add3c4200febcbc,
title = "Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?",
abstract = "Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms including reduced platelet function and number, leading to challenging peri-operative planning. Hepatic thrombopoietin (TPO) synthesis is reduced in CLD, leading to several recent randomized, placebo-controlled trials examining the utility of TPO-mimetics to increase platelet counts prior to surgery. While these trials do suggest that TPO-mimetics are efficacious at increasing platelet counts in patients with CLD and have led to several recent drug approvals in this space by the U.S. Food & Drug Administration, it remains unclear whether these results translate to the relevant clinical endpoint of reduced perioperative bleeding rate and severity. In this article, we review several recently-published, phase 3 trials on the TPO-mimetics eltrombopag, avatrombopag and lusutrombopag, and discuss the clinical significance of their results.",
keywords = "Bleeding, Platelets, thrombopoietin",
author = "Olson, {Sven R.} and Steven Koprowski and Justine Hum and Owen McCarty and Thomas Deloughery and Shatzel, {Joseph J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/09537104.2018.1542125",
language = "English (US)",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

AU - Olson, Sven R.

AU - Koprowski, Steven

AU - Hum, Justine

AU - McCarty, Owen

AU - Deloughery, Thomas

AU - Shatzel, Joseph J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms including reduced platelet function and number, leading to challenging peri-operative planning. Hepatic thrombopoietin (TPO) synthesis is reduced in CLD, leading to several recent randomized, placebo-controlled trials examining the utility of TPO-mimetics to increase platelet counts prior to surgery. While these trials do suggest that TPO-mimetics are efficacious at increasing platelet counts in patients with CLD and have led to several recent drug approvals in this space by the U.S. Food & Drug Administration, it remains unclear whether these results translate to the relevant clinical endpoint of reduced perioperative bleeding rate and severity. In this article, we review several recently-published, phase 3 trials on the TPO-mimetics eltrombopag, avatrombopag and lusutrombopag, and discuss the clinical significance of their results.

AB - Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms including reduced platelet function and number, leading to challenging peri-operative planning. Hepatic thrombopoietin (TPO) synthesis is reduced in CLD, leading to several recent randomized, placebo-controlled trials examining the utility of TPO-mimetics to increase platelet counts prior to surgery. While these trials do suggest that TPO-mimetics are efficacious at increasing platelet counts in patients with CLD and have led to several recent drug approvals in this space by the U.S. Food & Drug Administration, it remains unclear whether these results translate to the relevant clinical endpoint of reduced perioperative bleeding rate and severity. In this article, we review several recently-published, phase 3 trials on the TPO-mimetics eltrombopag, avatrombopag and lusutrombopag, and discuss the clinical significance of their results.

KW - Bleeding

KW - Platelets

KW - thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=85057327467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057327467&partnerID=8YFLogxK

U2 - 10.1080/09537104.2018.1542125

DO - 10.1080/09537104.2018.1542125

M3 - Article

AN - SCOPUS:85057327467

JO - Platelets

JF - Platelets

SN - 0953-7104

ER -